### Introduction: A Unique Investment Landscape

March 2026 is providing long-term investors with a rare scenario: market pullbacks that are not just a product of speculation, but rather emerge alongside improving fundamentals. This convergence of circumstances presents a compelling opportunity to consider investments in companies that are not simply chasing trends but are instead grounded in solid, sustainable business models.

In this article, we delve into four companies that are not only generating real revenue but are also positioned for continued growth in their respective markets. Each of these firms operates within sectors that are integral to everyday life, thus reducing the likelihood of their business models becoming obsolete. Let’s analyze why these companies could represent strong investment opportunities this March.

### 1. Axon Enterprise: Transforming Public Safety

**Company Overview**

Axon Enterprise, listed on NASDAQ under the ticker AXON, is best known for its development of TASERs and body cameras, crucial tools for law enforcement. However, to view Axon solely as a hardware manufacturer would be an oversimplification. The company has undergone a significant transformation into an **artificial intelligence (AI)-powered public safety platform**, enhancing its value proposition in a modernizing law enforcement landscape.

**Financial Performance**

In the fourth quarter of 2025, Axon reported impressive revenue figures of $797 million, marking a **39% year-over-year increase**. Over the full year, revenue reached $2.8 billion, demonstrating consistent growth for the fourth consecutive year at rates exceeding **30%**. Notably, Axon’s annual recurring revenue surpassed **$1.3 billion**, a growth rate of **35%**. Furthermore, the company boasts total future contracted bookings of **$14.4 billion**, reflecting an impressive **43%** increase.

**Strategic Growth Initiatives**

Looking ahead, Axon has set an ambitious target of achieving **$6 billion** in annual revenue by 2028, with an anticipated **28% adjusted EBITDA margin**. This roadmap includes innovations such as:

– **Axon 911**: An integration of services through acquisitions of Prepared and Carbyne.
– **Axon Vehicle Intelligence**: Enhancing the decision-making capabilities of law enforcement vehicles.
– **Axon Assistant**: An AI-driven tool aimed at automating police report writing.

Despite a premium valuation, Axon’s solid execution and growth trajectory position it as a promising long-term investment.

### 2. Vertiv: Powering the Future of AI Infrastructure

**Company Overview**

Vertiv, traded under the ticker VRT, plays a critical role in the burgeoning AI infrastructure sector, supplying essential power and cooling solutions for data centers that host AI models. As the demand for AI continues to rise, Vertiv finds itself in a prime position to capitalize on this growth.

**Impressive Financial Metrics**

In 2025, Vertiv achieved total revenue of **$10.2 billion**, an increase of **28%** year over year. Adjusted operating margins expanded to **20.4%**, indicating effective cost management. The company saw organic orders surge by an astounding **81%**, concluding the year with a backlog of **$15 billion**, which represents more than a full year of revenue. Adjusted free cash flow also soared to **$1.89 billion**, reflecting a **66%** increase.

**Innovations and Partnerships**

In late February 2026, Vertiv unveiled its **OneCore integrated modular solutions** and a **Digital Twin platform**, specifically designed for high-density AI data centers. This launch is bolstered by a strategic partnership with Hut 8, further solidifying Vertiv’s footprint in the market. The company’s management targets operating margins of **22% to 24%** over the medium term, indicating confidence in its growth strategy.

### 3. TransMedics Group: Revolutionizing Organ Transplantation

**Company Overview**

TransMedics Group, under the ticker TMDX, operates the **Organ Care System (OCS)**, a groundbreaking technology that maintains donor organs in a warm, functioning state during transport. This innovation replaces the traditional method of cooling organs in ice, which has been the standard for decades. The company also manages its own aviation fleet dedicated to organ transport, enhancing its logistical capabilities.

**Strong Financial Growth**

TransMedics reported a remarkable **37% increase** in revenue, reaching **$605.5 million** in 2025. Notably, the OCS Liver technology now accounts for **36%** of all liver transplant procedures in the U.S., demonstrating its impact in the healthcare sector. The company successfully completed **5,139 OCS transplants** in 2025, up from **3,735** in the previous year.

**Future Outlook and Expansion**

With an operating profit of **$21.3 million** in Q4, representing **13.2%** of revenue, and a net income of **$190.3 million** for the year, TransMedics is on a solid financial footing. The company has guided for 2026 revenues between **$727 million** and **$757 million**, indicating expected growth rates of **20% to 25%**. Furthermore, TransMedics holds FDA approvals for trials related to heart and lung organ transplants, and it is expanding its market reach into Europe, including Italy, which positions it uniquely in a market with no viable competitors.

### 4. Fair Isaac: The Credit Scoring Powerhouse

**Company Overview**

Fair Isaac Corporation, known by its ticker FICO, is the quintessential credit score company. Its FICO score is a critical element in the decision-making processes for mortgages, auto loans, and credit cards across the United States. With significant pricing power, the company has established itself as a near-monopoly in the credit scoring industry.

**Solid Financial Performance**

In fiscal year 2025, Fair Isaac reported revenues of **$1.99 billion**, reflecting a **15.9%** increase. The company achieved a net income of **$651.9 million** with a robust **32.8% net profit margin**. In Q4, FICO’s revenue reached **$512 million**, alongside an impressive **45.7% operating margin**. Over the past decade, earnings per share (EPS) have grown at an annual average rate of **22.2%**, showcasing the company’s consistent financial health.

**Catalysts for Future Growth**

A key driver for Fair Isaac’s future growth is the introduction of **FICO Score 10T**, a more predictive scoring model that incorporates trended credit data. Initially met with skepticism, the model’s adoption in the conforming mortgage market is expected to significantly enhance licensing revenue over the coming years. Additionally, FICO is expanding its software analytics business, broadening its addressable market beyond traditional credit scoring.

In a market where the stock has corrected by around **25%** year-to-date, this presents a unique entry point for investors looking to capitalize on a near-monopoly with expanding profit margins. The recent announcement of a **$1.5 billion stock buyback** further underscores the company’s commitment to enhancing shareholder value.

### Conclusion: A Balanced Perspective on Investment Opportunities

As investors weigh potential opportunities in March 2026, the companies highlighted in this article—Axon Enterprise, Vertiv, TransMedics Group, and Fair Isaac—represent diverse sectors with strong growth potential. Each company combines innovative technology with robust financial health, creating a solid foundation for long-term investment.

However, it is essential to approach these opportunities with a balanced perspective, considering external market factors, competitive dynamics, and the inherent risks associated with each industry. By conducting thorough research and maintaining a long-term investment horizon, investors can position themselves to capitalize on these promising stocks in the months ahead.

Ultimately, the investment landscape may be volatile, but with a strategic focus on companies that demonstrate genuine growth and innovation, long-term investors can navigate these challenges effectively.

Source: https://www.fool.com/investing/2026/03/08/top-stocks-long-term-investors-should-buy-in-march/